{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:07Z","timestamp":1789362307398,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Commercial genomic profiling is increasingly used in oncology practice, yet translating reported alterations into treatment decisions remains challenging. Differences across assays, variable evidence levels, and limited access to molecular tumor boards mean that interpretation often depends on the treating clinician rather than the report alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Perspective<\/jats:title>\n                    <jats:p>We describe a structured clinical approach to interpreting commercially generated genomic reports in routine oncology practice using curated public genomic resources, targeted literature review, and clinical feasibility assessment. This approach was developed in a private oncology practice in Jordan to support treatment decisions when formal molecular tumor board access is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Illustrative application<\/jats:title>\n                    <jats:p>Two clinical scenarios demonstrate both consideration of targeted therapy in the setting of a biologically plausible but weakly annotated alteration and recognition of non-actionability when genomic findings do not justify deviation from disease-specific management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Structured interpretation can support more consistent clinical decision making around genomic findings, particularly when molecular tumor boards are not readily available. It may help bridge the gap between access to sequencing and meaningful clinical application in routine oncology practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1864818","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:28Z","timestamp":1789360708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Making sense of commercial genomic reports in oncology: a structured approach from clinical practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Ameer","family":"Gharaybeh","sequence":"first","affiliation":[{"name":"Stratford Preparatory High School","place":["San Jose, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Al-Sukhun","sequence":"additional","affiliation":[{"name":"Al Hyatt Oncology Practice","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the association for molecular pathology and college of american pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0097","article-title":"Implementation of a molecular tumor board: The impact on treatment decisions for 35 patients evaluated at dartmouth-hitchcock medical center","volume":"20","author":"Tafe","year":"2015","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16057","article-title":"Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery","volume":"8","author":"Bryce","year":"2017","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1535","article-title":"Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma","volume":"17","author":"Al-Sukhun","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2019.01.006","article-title":"A practical guide to validation and verification of analytical methods in the clinical laboratory","volume":"90","author":"Pum","year":"2019","journal-title":"Adv Clin Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100570","article-title":"How to read a next-generation sequencing report-what oncologists need to know","volume":"7","author":"Schmid","year":"2022","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21825","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00615","article-title":"Concordance in molecular tumor board case reviews in the ASCO TAPUR study","volume":"8","author":"Perez","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00011","article-title":"Molecular tumor board improves outcomes for hispanic patients with advanced solid tumors","volume":"10","author":"Sotelo-Rodriguez","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.34172\/hpp.2023.23","article-title":"Virtual tumor boards: An approach to equity in cancer care","volume":"13","author":"AkbariRad","year":"2023","journal-title":"Health Promot Perspect"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/go-24-00416","article-title":"Precision oncology: A global perspective on implementation and policy development","volume":"11","author":"Horgan","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/go.24.00015","article-title":"Global equity in clinical trials: An ASCO policy statement","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.2431","article-title":"Global curriculum edition 2016: European society for medical oncology\/american society of clinical oncology recommendations for training in medical oncology","volume":"35","author":"Dittrich","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:35Z","timestamp":1789360715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1864818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1864818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1864818"}}